RxDoctor Payments Data

Christian Ellison, MD

Family Medicine · Westfield, NJNPI 1306838305

Payments from drug & device makers

$2,303in general payments, 2019–2025

Across 149 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$289
  • Merck$285
  • AstraZeneca$235
  • Novo Nordisk$211
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$154
  • Viiv Healthcare Company$138
  • plus $990 from 20 others

What the payments were for

  • Consulting fees$27512%
  • Food & beverage$2,00987%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,303 in reported general payments places this provider in the 75th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$237,876
Medicare patients
505
Services billed
3,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$61,242
TrulicityDulaglutide51$55,540
MounjaroTirzepatide43$50,540
Xigduo XrDapaglifloz Propaned/Metformin30$36,439
JanuviaSitagliptin Phosphate41$35,782
OzempicSemaglutide24$33,771
EliquisApixaban17$23,828
XareltoRivaroxaban13$21,163
Janumet XrSitagliptin Phos/Metformin Hcl19$18,972
WegovySemaglutide14$18,790
JanumetSitagliptin Phos/Metformin Hcl12$17,753
Synjardy XrEmpagliflozin/Metformin Hcl11$17,734
VascepaIcosapent Ethyl15$9,388
Carvedilol ErCarvedilol Phosphate12$5,335
Atorvastatin Calcium518$4,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$112$106,08094 claims
Boehringer IngelheimJardiance, Synjardy Xr$26$78,97651 claims
MerckJanuvia, Janumet Xr, Janumet$285$72,50772 claims
Novo NordiskOzempic, Wegovy$211$52,56138 claims
PfizerEliquis$52$23,82817 claims
Johnson & JohnsonXarelto$99$21,16313 claims
AbbVieSynthroid$13$2,49830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Westfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →